登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C20H21ClO4
化学文摘社编号:
分子量:
360.83
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
pharmaceutical primary standard
API family
fenofibrate
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2
InChI
1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3
InChI key
YMTINGFKWWXKFG-UHFFFAOYSA-N
Gene Information
human ... PPARA(5465)
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Fenofibrate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Fenofibrate Capsules
- Fenofibrate Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under 非诺贝特
signalword
Warning
hcodes
pcodes
Hazard Classifications
STOT RE 2 Oral
target_organs
Liver
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Michel P Hermans
Diabetes & vascular disease research, 8(3), 180-189 (2011-05-18)
Microvascular complications are common in type 2 diabetes in primary care. Intensified management of glycaemia or blood pressure had little effect on microvascular complication rates in recent large trials (ADVANCE, VADT, ACCORD). In 2005, the FIELD study demonstrated a significant
Pitchai Balakumar et al.
Pharmacological research, 63(1), 8-12 (2010-11-26)
Fenofibrate is a third-generation fibric acid derivative employed clinically as a hypolipidemic agent to lessen the risk caused by atherosclerosis. Dyslipidemia is a condition associated with elevated levels of low-density lipoproteins (LDL), very low-density lipoproteins (VLDL) and triglycerides, and reduced
Itoro E Elijah et al.
Burns : journal of the International Society for Burn Injuries, 38(4), 481-486 (2012-01-10)
Fenofibrate is a peroxisome proliferator activated receptor alpha agonist that contains both pro and anti-inflammatory properties, and has been used in the treatment of dyslipidemia and diabetes for decades. Its receptors are expressed in the liver, skeletal muscle, cardiac, enteric
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 1269447-200MG | 04061838724540 |